DealsMay 4, 2026, 07:32 AM
MacroGenics Expands ZYNYZ Royalty Deal with Sagard for $60M Upfront
AI Summary
MacroGenics, Inc. announced an expanded royalty purchase agreement with Sagard for a capped royalty interest on future global net sales of ZYNYZ® (retifanlimab-dlwr). Under the amended terms, MacroGenics received a $60 million upfront payment and is eligible for an additional 2026 sales-based milestone of up to $20 million. Royalty rights will revert to MacroGenics once Sagard has received total payments of either 1.7x its investment by September 30, 2032, or 2.0x its investment at any time thereafter, while MacroGenics retains other economic interests.
Key Highlights
- MacroGenics expanded its royalty purchase agreement with Sagard for ZYNYZ® (retifanlimab-dlwr).
- MacroGenics received a $60 million upfront payment from Sagard.
- The company is eligible for an additional 2026 sales-based milestone of up to $20 million.
- Royalty rights revert to MacroGenics once Sagard receives 1.7x its investment by September 30, 2032.
- Alternatively, royalty rights revert if Sagard receives 2.0x its investment at any time thereafter.
- MacroGenics retains other economic interests related to ZYNYZ, including future milestones.